<!DOCTYPE html>
<html>
<head>
<meta http-equiv="X-UA-Compatible" content="IE=Edge" />
<meta charset="utf-8" />
</head>

<body style="margin: 0;">

<div id="p57" style="overflow: hidden; position: relative; background-color: white; width: 1210px; height: 935px;">
<style class="shared-css" type="text/css" >
.t {
	transform-origin: bottom left;
	z-index: 2;
	position: absolute;
	white-space: pre;
	overflow: visible;
	line-height: 1.5;
}
.text-container {
	white-space: pre;
}
@supports (-webkit-touch-callout: none) {
	.text-container {
		white-space: normal;
	}
}
</style>
<style type="text/css" >

#t1_57{left:36px;bottom:25px;letter-spacing:0.07px;word-spacing:0.01px;}
#t2_57{left:341px;bottom:30px;}
#t3_57{left:348px;bottom:25px;letter-spacing:0.11px;}
#t4_57{left:377px;bottom:30px;}
#t5_57{left:381px;bottom:25px;letter-spacing:0.07px;word-spacing:-0.1px;}
#t6_57{left:540px;bottom:30px;}
#t7_57{left:546px;bottom:25px;letter-spacing:0.07px;}
#t8_57{left:44px;bottom:77px;letter-spacing:0.1px;word-spacing:-0.05px;}
#t9_57{left:44px;bottom:63px;letter-spacing:0.1px;}
#ta_57{left:285px;bottom:860px;letter-spacing:-0.32px;word-spacing:0.06px;}
#tb_57{left:285px;bottom:827px;letter-spacing:-0.24px;}
#tc_57{left:996px;bottom:873px;letter-spacing:-0.1px;}
#td_57{left:1043px;bottom:853px;letter-spacing:-0.22px;word-spacing:0.13px;}
#te_57{left:1093px;bottom:833px;letter-spacing:-0.09px;}
#tf_57{left:1095px;bottom:47px;letter-spacing:0.38px;}
#tg_57{left:1121px;bottom:28px;letter-spacing:0.19px;word-spacing:-0.15px;}
#th_57{left:36px;bottom:344px;}
#ti_57{left:46px;bottom:338px;letter-spacing:0.08px;word-spacing:-0.01px;}
#tj_57{left:377px;bottom:338px;letter-spacing:0.12px;}
#tk_57{left:407px;bottom:338px;letter-spacing:0.13px;}
#tl_57{left:481px;bottom:338px;}
#tm_57{left:36px;bottom:328px;}
#tn_57{left:46px;bottom:322px;letter-spacing:0.13px;word-spacing:-0.03px;}
#to_57{left:36px;bottom:313px;}
#tp_57{left:46px;bottom:307px;letter-spacing:0.1px;word-spacing:-0.02px;}
#tq_57{left:45px;bottom:292px;letter-spacing:0.13px;}
#tr_57{left:36px;bottom:282px;}
#ts_57{left:46px;bottom:276px;letter-spacing:0.12px;word-spacing:0.01px;}
#tt_57{left:36px;bottom:267px;}
#tu_57{left:46px;bottom:261px;letter-spacing:0.12px;word-spacing:-0.03px;}
#tv_57{left:557px;bottom:261px;}
#tw_57{left:36px;bottom:252px;}
#tx_57{left:46px;bottom:246px;letter-spacing:0.12px;}
#ty_57{left:45px;bottom:231px;letter-spacing:0.13px;}
#tz_57{left:451px;bottom:239px;}
#t10_57{left:456px;bottom:231px;letter-spacing:0.12px;word-spacing:0.01px;}
#t11_57{left:45px;bottom:215px;letter-spacing:0.12px;word-spacing:0.01px;}
#t12_57{left:45px;bottom:200px;letter-spacing:0.11px;word-spacing:0.02px;}
#t13_57{left:45px;bottom:185px;letter-spacing:0.13px;}
#t14_57{left:45px;bottom:170px;letter-spacing:0.11px;word-spacing:0.02px;}
#t15_57{left:45px;bottom:154px;letter-spacing:0.12px;}
#t16_57{left:45px;bottom:139px;letter-spacing:0.12px;}
#t17_57{left:45px;bottom:124px;letter-spacing:0.12px;}
#t18_57{left:45px;bottom:108px;letter-spacing:0.12px;}
#t19_57{left:438px;bottom:778px;letter-spacing:0.39px;word-spacing:-0.22px;}
#t1a_57{left:765px;bottom:786px;}
#t1b_57{left:36px;bottom:748px;letter-spacing:-0.1px;}
#t1c_57{left:36px;bottom:729px;letter-spacing:-0.11px;word-spacing:-0.62px;}
#t1d_57{left:36px;bottom:711px;letter-spacing:-0.09px;}
#t1e_57{left:455px;bottom:718px;}
#t1f_57{left:36px;bottom:693px;letter-spacing:-0.1px;}
#t1g_57{left:42px;bottom:674px;}
#t1h_57{left:58px;bottom:674px;letter-spacing:-0.09px;}
#t1i_57{left:58px;bottom:656px;letter-spacing:-0.09px;}
#t1j_57{left:58px;bottom:638px;letter-spacing:-0.09px;}
#t1k_57{left:64px;bottom:619px;}
#t1l_57{left:77px;bottom:619px;letter-spacing:-0.09px;}
#t1m_57{left:77px;bottom:601px;letter-spacing:-0.1px;}
#t1n_57{left:308px;bottom:608px;}
#t1o_57{left:64px;bottom:583px;}
#t1p_57{left:77px;bottom:583px;letter-spacing:-0.16px;word-spacing:0.06px;}
#t1q_57{left:77px;bottom:564px;}
#t1r_57{left:91px;bottom:564px;letter-spacing:-0.09px;}
#t1s_57{left:91px;bottom:546px;letter-spacing:-0.09px;}
#t1t_57{left:77px;bottom:528px;letter-spacing:-0.09px;word-spacing:-0.04px;}
#t1u_57{left:64px;bottom:509px;}
#t1v_57{left:77px;bottom:509px;letter-spacing:-0.09px;}
#t1w_57{left:42px;bottom:491px;}
#t1x_57{left:58px;bottom:491px;letter-spacing:-0.09px;}
#t1y_57{left:64px;bottom:473px;}
#t1z_57{left:77px;bottom:473px;letter-spacing:-0.09px;}
#t20_57{left:547px;bottom:480px;}
#t21_57{left:671px;bottom:748px;letter-spacing:0.34px;word-spacing:-0.18px;}
#t22_57{left:1013px;bottom:755px;letter-spacing:-0.12px;}
#t23_57{left:671px;bottom:729px;letter-spacing:-0.1px;}
#t24_57{left:676px;bottom:711px;}
#t25_57{left:693px;bottom:711px;letter-spacing:-0.12px;word-spacing:0.03px;}
#t26_57{left:676px;bottom:693px;}
#t27_57{left:693px;bottom:693px;letter-spacing:-0.09px;}
#t28_57{left:693px;bottom:674px;letter-spacing:-0.09px;}
#t29_57{left:952px;bottom:682px;}
#t2a_57{left:35px;bottom:426px;letter-spacing:-0.09px;word-spacing:-0.05px;}
#t2b_57{left:35px;bottom:408px;letter-spacing:-0.11px;word-spacing:-0.02px;}
#t2c_57{left:35px;bottom:389px;letter-spacing:-0.1px;}
#t2d_57{left:35px;bottom:371px;letter-spacing:-0.11px;}
#t2e_57{left:23px;bottom:915px;letter-spacing:-0.14px;}

.s0_57{font-size:9px;font-family:ArialMT_5tg;color:#000;}
.s1_57{font-size:5px;font-family:ArialMT_5tg;color:#000;}
.s2_57{font-size:12px;font-family:Arial-BoldMT_5te;color:#000;}
.s3_57{font-size:28px;font-family:Arial-BoldMT_5te;color:#000;}
.s4_57{font-size:17px;font-family:ArialMT_5tg;color:#0065A4;}
.s5_57{font-size:17px;font-family:Arial-BoldMT_5te;color:#000;}
.s6_57{font-size:12px;font-family:ArialMT_5tg;color:#000;}
.s7_57{font-size:15px;font-family:ArialMT_5tg;color:#0065A4;}
.s8_57{font-size:15px;font-family:ArialMT_5tg;color:#000;}
.s9_57{font-size:15px;font-family:ArialMT_k0;color:#000;}
.sa_57{font-size:14px;font-family:Arial-BoldMT_5te;color:#000;}
.sb_57{font-size:17px;font-family:Webdings_k6;color:#000;}
.sc_57{font-size:17px;font-family:Arial-BoldMT_jz;color:#000;}
.sd_57{font-size:17px;font-family:SymbolMT_ka;color:#000;}
.se_57{font-size:11px;font-family:Helvetica, Arial, sans-serif;color:#000;}
</style>
<style id="fonts57" type="text/css" >

@font-face {
	font-family: Arial-BoldMT_5te;
	src: url("fonts/Arial-BoldMT_5te.woff") format("woff");
}

@font-face {
	font-family: Arial-BoldMT_jz;
	src: url("fonts/Arial-BoldMT_jz.woff") format("woff");
}

@font-face {
	font-family: ArialMT_5tg;
	src: url("fonts/ArialMT_5tg.woff") format("woff");
}

@font-face {
	font-family: ArialMT_k0;
	src: url("fonts/ArialMT_k0.woff") format("woff");
}

@font-face {
	font-family: SymbolMT_ka;
	src: url("fonts/SymbolMT_ka.woff") format("woff");
}

@font-face {
	font-family: Webdings_k6;
	src: url("fonts/Webdings_k6.woff") format("woff");
}

</style>
<div id="pg57Overlay" style="width:100%; height:100%; position:absolute; z-index:1; background-color:rgba(0,0,0,0); -webkit-user-select: none;"></div>
<div id="pg57" style="-webkit-user-select: none;"><object width="1210" height="935" data="57/57.svg" type="image/svg+xml" id="pdf57" style="width:1210px; height:935px; z-index: 0;"></object></div>
<div class="text-container"><span id="t1_57" class="t s0_57">Version 4.2024, 5/1/2024 © 2024 National Comprehensive Cancer Network </span>
<span id="t2_57" class="t s1_57">® </span>
<span id="t3_57" class="t s0_57">(NCCN </span>
<span id="t4_57" class="t s1_57">® </span>
<span id="t5_57" class="t s0_57">), All rights reserved. NCCN Guidelines </span>
<span id="t6_57" class="t s1_57">® </span>
<span id="t7_57" class="t s0_57">and this illustration may not be reproduced in any form without the express written permission of NCCN. </span>
<span id="t8_57" class="t s2_57">Note: All recommendations are category 2A unless otherwise indicated. </span>
<span id="t9_57" class="t s2_57">Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged. </span>
<span id="ta_57" class="t s3_57">NCCN Guidelines Version 4.2024 </span>
<span id="tb_57" class="t s3_57">Cancer of the Supraglottic Larynx </span>
<span id="tc_57" class="t s4_57">NCCN Guidelines Index </span>
<span id="td_57" class="t s4_57">Table of Contents </span>
<span id="te_57" class="t s4_57">Discussion </span>
<span id="tf_57" class="t s5_57">SUPRA-A </span>
<span id="tg_57" class="t s5_57">1 OF 2 </span>
<span id="th_57" class="t s6_57">1 </span>
<span id="ti_57" class="t s7_57">See Principles of Radiation Techniques (RAD-A) </span><span id="tj_57" class="t s8_57">and </span><span id="tk_57" class="t s7_57">Discussion</span><span id="tl_57" class="t s8_57">. </span>
<span id="tm_57" class="t s6_57">2 </span>
<span id="tn_57" class="t s8_57">For select T1–2,N0 tumors, accelerated fractionation may be used. </span>
<span id="to_57" class="t s6_57">3 </span>
<span id="tp_57" class="t s9_57">For doses &gt;70 Gy, some clinicians feel that the fractionation should be slightly modified (eg, &lt;2.0 Gy/fraction for at least some of the treatment) to minimize toxicity. An </span>
<span id="tq_57" class="t s8_57">additional 2–3 doses can be added depending on clinical circumstances. </span>
<span id="tr_57" class="t s6_57">4 </span>
<span id="ts_57" class="t s8_57">Suggest 44–50 Gy in 3D-CRT and sequentially planned IMRT or 54–63 Gy with IMRT dose painting technique (dependent on dose per fraction). </span>
<span id="tt_57" class="t s6_57">5 </span>
<span id="tu_57" class="t s7_57">Principles of Systemic Therapy for Non-Nasopharyngeal Cancers (SYST-A)</span><span id="tv_57" class="t s8_57">. </span>
<span id="tw_57" class="t s6_57">6 </span>
<span id="tx_57" class="t s8_57">Based on published data, concurrent systemic therapy/RT most commonly uses conventional fractionation at 2.0 Gy per fraction to a typical dose of 70 Gy in 7 weeks </span>
<span id="ty_57" class="t s8_57">with single-agent cisplatin given every 3 weeks at 100 mg/m </span>
<span id="tz_57" class="t s0_57">2 </span>
<span id="t10_57" class="t s8_57">; 2–3 cycles of chemotherapy are used depending on the radiation fractionation scheme (RTOG) (Ang </span>
<span id="t11_57" class="t s8_57">KK, Harris J, Wheeler R, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med 2010;363:24-35). When carboplatin and </span>
<span id="t12_57" class="t s8_57">5-FU are used, the recommended regimen is standard fractionation plus 3 cycles of chemotherapy [Bourhis J, Sire C, Graff P, et al. Concomitant chemoradiotherapy </span>
<span id="t13_57" class="t s8_57">versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase </span>
<span id="t14_57" class="t s9_57">3 randomised trial. Lancet Oncol 2012;13:145-153]. Other fraction sizes (eg, 1.8 Gy, conventional), multiagent chemotherapy, other dosing schedules of cisplatin, or </span>
<span id="t15_57" class="t s8_57">altered fractionation with chemotherapy are efficacious, and there is no consensus on the optimal approach. In general, the use of concurrent systemic therapy/RT </span>
<span id="t16_57" class="t s8_57">carries a high toxicity burden; multiagent chemotherapy will likely further increase the toxicity burden. For any systemic therapy/RT approach, close attention should </span>
<span id="t17_57" class="t s8_57">be paid to published reports for the specific chemotherapy agent, dose, and schedule of administration. Systemic therapy/RT should be performed by an experienced </span>
<span id="t18_57" class="t s8_57">team and should include substantial supportive care. </span>
<span id="t19_57" class="t s5_57">PRINCIPLES OF RADIATION THERAPY </span>
<span id="t1a_57" class="t sa_57">1 </span>
<span id="t1b_57" class="t s5_57">DEFINITIVE: </span>
<span id="t1c_57" class="t s5_57">RT Alone </span>
<span id="t1d_57" class="t s5_57">• T1–3,N0–1: 66–70 Gy conventional (2.0 Gy/fraction) </span>
<span id="t1e_57" class="t sa_57">2 </span>
<span id="t1f_57" class="t s5_57">• PTV </span>
<span id="t1g_57" class="t sb_57"></span><span id="t1h_57" class="t s5_57">High risk: Primary tumor and involved lymph nodes [this includes </span>
<span id="t1i_57" class="t sc_57" data-mappings='[[29,"fi"]]'>possible local subclinical inﬁltration at the primary site and at the high- </span>
<span id="t1j_57" class="t s5_57">risk level lymph node(s)] </span>
<span id="t1k_57" class="t sd_57">◊ </span><span id="t1l_57" class="t s5_57">Fractionation: 66 Gy (2.2 Gy/fraction) to 70 Gy (2.0 Gy/fraction); daily </span>
<span id="t1m_57" class="t s5_57">Monday–Friday in 6–7 weeks </span>
<span id="t1n_57" class="t sa_57">3 </span>
<span id="t1o_57" class="t sd_57">◊ </span><span id="t1p_57" class="t s5_57">Concomitant boost accelerated RT: </span>
<span id="t1q_57" class="t s5_57">– </span><span id="t1r_57" class="t sc_57" data-mappings='[[38,"fi"]]'>72 Gy/6 weeks (1.8 Gy/fraction, large ﬁeld; 1.5 Gy boost as second </span>
<span id="t1s_57" class="t s5_57">daily fraction during last 12 treatment days) </span>
<span id="t1t_57" class="t s5_57">– 66–70 Gy (2.0 Gy/fraction; 6 fractions/wk accelerated) </span>
<span id="t1u_57" class="t sd_57">◊ </span><span id="t1v_57" class="t s5_57">Hyperfractionation: 79.2–81.6 Gy/7 weeks (1.2 Gy/fraction twice daily) </span>
<span id="t1w_57" class="t sb_57"></span><span id="t1x_57" class="t s5_57">Low to intermediate risk: Sites of suspected subclinical spread </span>
<span id="t1y_57" class="t sd_57">◊ </span><span id="t1z_57" class="t s5_57">44–50 Gy (2.0 Gy/fraction) to 54–63 Gy (1.6–1.8 Gy/fraction) </span>
<span id="t20_57" class="t sa_57">4 </span>
<span id="t21_57" class="t s5_57">CONCURRENT SYSTEMIC THERAPY/RT: </span>
<span id="t22_57" class="t sa_57">5,6 </span>
<span id="t23_57" class="t s5_57">• PTV </span>
<span id="t24_57" class="t sb_57"></span><span id="t25_57" class="t s5_57">High risk: Typically 70 Gy (2.0 Gy/fraction) </span>
<span id="t26_57" class="t sb_57"></span><span id="t27_57" class="t s5_57">Low to intermediate and low risk: 44–50 Gy (2.0 Gy/fraction) </span>
<span id="t28_57" class="t s5_57">to 54–63 Gy (1.6–1.8 Gy/fraction) </span>
<span id="t29_57" class="t sa_57">4 </span>
<span id="t2a_57" class="t s5_57">Either IMRT (preferred) or 3D-CRT is recommended. Use of proton therapy is an area of active investigation. </span>
<span id="t2b_57" class="t s5_57">Proton therapy may be considered when normal tissue constraints cannot be met by photon-based therapy, </span>
<span id="t2c_57" class="t s5_57">or when photon-based therapy causes compromise of standard radiation dosing to tumor or postoperative </span>
<span id="t2d_57" class="t s5_57">volumes. </span>
<span id="t2e_57" class="t se_57">Printed by Fredd Merc on 8/29/2024 4:45:54 AM. For personal use only. Not approved for distribution. Copyright © 2024 National Comprehensive Cancer Network, Inc., All Rights Reserved. </span></div>

</div>
</body>
</html>
